Atopic Dermatitis - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 281 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Atopic Dermatitis - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Atopic Dermatitis - Pipeline Review, H2 2014', provides an overview of the Atopic Dermatitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Atopic Dermatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atopic Dermatitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Atopic Dermatitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Atopic Dermatitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Atopic Dermatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Atopic Dermatitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Atopic Dermatitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Atopic Dermatitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Atopic Dermatitis Overview 11
Therapeutics Development 12
Pipeline Products for Atopic Dermatitis - Overview 12
Pipeline Products for Atopic Dermatitis - Comparative Analysis 13
Atopic Dermatitis - Therapeutics under Development by Companies 14
Atopic Dermatitis - Therapeutics under Investigation by Universities/Institutes 20
Atopic Dermatitis - Pipeline Products Glance 21
Late Stage Products 21
Clinical Stage Products 22
Early Stage Products 23
Atopic Dermatitis - Products under Development by Companies 24
Atopic Dermatitis - Products under Investigation by Universities/Institutes 29
Atopic Dermatitis - Companies Involved in Therapeutics Development 30
Bristol-Myers Squibb Company 30
Johnson & Johnson 31
Kyowa Hakko Kirin Co., Ltd. 32
Valeant Pharmaceuticals International, Inc. 33
Daiichi Sankyo Company, Limited 34
Merck & Co., Inc. 35
Taisho Pharmaceutical Co., Ltd. 36
Takeda Pharmaceutical Company Limited 37
Novartis AG 38
Amorepacific Corporation 39
Chugai Pharmaceutical Co., Ltd. 40
Eisai Co., Ltd. 41
LEO Pharma A/S 42
Mitsubishi Tanabe Pharma Corporation 43
Pfizer Inc. 44
Celgene Corporation 45
Bayer AG 46
AlbireoPharma 47
NicOx S.A. 48
Nuvo Research Inc. 49
Yungjin Pharm Ind. Co., Ltd. 50
Regeneron Pharmaceuticals, Inc. 51
HanAll Biopharma Co., Ltd. 52
AnGes MG, Inc. 53
Provectus Biopharmaceuticals, Inc. 54
R-Tech Ueno, Ltd. 55
Paloma Pharmaceuticals, Inc. 56
Upsher-Smith Laboratories, Inc. 57
Foamix Ltd. 58
Anacor Pharmaceuticals, Inc. 59
AnaptysBio, Inc. 60
IMMD Inc. 61
Circassia Holdings Ltd. 62
Oxagen Limited 63
Melior Discovery, Inc. 64
Grupo Ferrer Internacional, S.A. 65
Xencor, Inc. 66
Welichem Biotech Inc. 67
ChemoCentryx, Inc. 68
Vitae Pharmaceuticals, Inc. 69
arGEN-X BV 70
SWITCH Biotech LLC 71
Promius Pharma, LLC 72
Celsus Therapeutics Plc 73
Pharis Biotec GmbH 74
Vicore Pharma AB 75
Otsuka Holdings Co., Ltd. 76
LegoChem Biosciences, Inc 77
Fountain Biopharma Inc. 78
Pergamum AB 79
VivaCell Biotechnology Espana S.L. 80
Brickell Biotech, Inc. 81
NeoPharm Co., Ltd. 82
Herantis Pharma plc. 83
Creabilis SA 84
Polyrizon Ltd. 85
sterna biologicals Gmbh & Co KG 85
Dermira Inc. 86
Istituto Italiano di Tecnologia 87
Thesan Pharmaceuticals, Inc. 88
ChironWells GmbH 89
Pharmedartis GmbH 90
Atopic Dermatitis - Therapeutics Assessment 91
Assessment by Monotherapy Products 91
Assessment by Target 92
Assessment by Mechanism of Action 96
Assessment by Route of Administration 100
Assessment by Molecule Type 102
Drug Profiles 105
KTG-001 - Drug Profile 105
DAN-2728 - Drug Profile 106
dupilumab - Drug Profile 108
roflumilast - Drug Profile 110
tofacitinib - Drug Profile 113
apremilast - Drug Profile 117
CT-327 - Drug Profile 119
ustekinumab - Drug Profile 121
PH-10 - Drug Profile 124
DPK-060 - Drug Profile 126
cobamamide - Drug Profile 127
OC-459 - Drug Profile 128
LEO-29102 - Drug Profile 130
MRX-6 - Drug Profile 131
WBI-1001 - Drug Profile 132
Small Molecule for Immunology, Ophthalmology, Oncology and Dermatology - Drug Profile 134
AN-2898 - Drug Profile 136
S-414114 - Drug Profile 138
mapracorat - Drug Profile 140
DRM-02 - Drug Profile 142
E-6005 - Drug Profile 143
fevipiprant - Drug Profile 144
TA-7906 - Drug Profile 146
QGE-031 - Drug Profile 147
SB-011 - Drug Profile 149
CIM-331 - Drug Profile 150
OPA-15406 - Drug Profile 151
KHK-4577 - Drug Profile 152
PDI-192 - Drug Profile 153
Drug for Atopic Dermatitis and Eczema - Drug Profile 154
DFD-06 - Drug Profile 155
BPR-277 - Drug Profile 156
mometasone furoate - Drug Profile 157
Furestem-AD - Drug Profile 158
BMS-981164 - Drug Profile 159
IMD-0354 - Drug Profile 160
ZPL-3893787 - Drug Profile 161
XmAb-7195 - Drug Profile 162
MK-8226 - Drug Profile 163
LEO-39652 - Drug Profile 164
Small Molecule for Atopic Dermatitis - Drug Profile 165
coagulation factor XIVa (human) - Drug Profile 166
NCX-1047 - Drug Profile 167
S-414114 - Drug Profile 168
SWT-01113 - Drug Profile 170
SWT-05141 - Drug Profile 171
Small Molecule to Antagonize PAR-2 for Atopic Dermatitis, Inflammatory Bowel Disease and Ulcerative Colitis - Drug Profile 172
RTU-1096 - Drug Profile 173
P-529 - Drug Profile 174
CIR-001 - Drug Profile 176
LEKTI-6 - Drug Profile 177
MLR-1130 - Drug Profile 178
A-3914 - Drug Profile 179
SIG-1311 - Drug Profile 180
C-21 - Drug Profile 181
RS-1269 - Drug Profile 183
SUN-0597 - Drug Profile 184
PAC-14028 - Drug Profile 186
CCX-6239 - Drug Profile 188
BBI-2111 - Drug Profile 189
NPB-3 - Drug Profile 190
HS-378 - Drug Profile 191
A-5425 - Drug Profile 192
betamethasone dipropionate - Drug Profile 193
Q-301 - Drug Profile 194
CDE-001 - Drug Profile 195
ARN-077 - Drug Profile 196
TKM-0150 - Drug Profile 197
ARGX-112 - Drug Profile 198
VTP-38543 - Drug Profile 199
AN-3485 - Drug Profile 200
PMA-101R - Drug Profile 201
PMA-201 - Drug Profile 202
PMA-411R - Drug Profile 203
FB-825 - Drug Profile 204
NPH-12 - Drug Profile 205
triamcinolone acetonide - Drug Profile 206
clobetasol propionate - Drug Profile 207
FP7 Project - Drug Profile 208
ANB-020 - Drug Profile 209
LCB-030110 - Drug Profile 210
N-Acylethanolamine Acid Amidase Inhibitors for Chronic Inflammation and Atopic Dermatitis - Drug Profile 211
P-10 - Drug Profile 212
WF-10 - Drug Profile 213
PL-601 - Drug Profile 215
Drug for Atopic Dermatitis - Drug Profile 216
FIB-116 - Drug Profile 217
Synthetic Peptide to Inhibit Kallikrein for Immunology, Dermatological and Genetic Disorders - Drug Profile 218
BB-2702 - Drug Profile 219
Small Molecule for Atopic Dermatitis - Drug Profile 220
Aptamers to Inhibit Galectin-3 for Atopic Dermatitis - Drug Profile 221
Atopic Dermatitis - Recent Pipeline Updates 222
Atopic Dermatitis - Dormant Projects 258
Atopic Dermatitis - Discontinued Products 265
Atopic Dermatitis - Product Development Milestones 266
Featured News & Press Releases 266
Appendix 274
Methodology 274
Coverage 274
Secondary Research 274
Primary Research 274
Expert Panel Validation 274
Contact Us 275
Disclaimer 275

List of Tables
Number of Products under Development for Atopic Dermatitis, H2 2014 18
Number of Products under Development for Atopic Dermatitis - Comparative Analysis, H2 2014 19
Number of Products under Development by Companies, H2 2014 21
Number of Products under Development by Companies, H2 2014 (Contd..1) 22
Number of Products under Development by Companies, H2 2014 (Contd..2) 23
Number of Products under Development by Companies, H2 2014 (Contd..3) 24
Number of Products under Development by Companies, H2 2014 (Contd..4) 25
Number of Products under Investigation by Universities/Institutes, H2 2014 26
Comparative Analysis by Late Stage Development, H2 2014 27
Comparative Analysis by Clinical Stage Development, H2 2014 28
Comparative Analysis by Early Stage Development, H2 2014 29
Products under Development by Companies, H2 2014 30
Products under Development by Companies, H2 2014 (Contd..1) 31
Products under Development by Companies, H2 2014 (Contd..2) 32
Products under Development by Companies, H2 2014 (Contd..3) 33
Products under Development by Companies, H2 2014 (Contd..4) 34
Products under Investigation by Universities/Institutes, H2 2014 35
Atopic Dermatitis - Pipeline by Bristol-Myers Squibb Company, H2 2014 36
Atopic Dermatitis - Pipeline by Johnson & Johnson, H2 2014 37
Atopic Dermatitis - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2014 38
Atopic Dermatitis - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2014 39
Atopic Dermatitis - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 40
Atopic Dermatitis - Pipeline by Merck & Co., Inc., H2 2014 41
Atopic Dermatitis - Pipeline by Taisho Pharmaceutical Co., Ltd., H2 2014 42
Atopic Dermatitis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 43
Atopic Dermatitis - Pipeline by Novartis AG, H2 2014 44
Atopic Dermatitis - Pipeline by Amorepacific Corporation, H2 2014 45
Atopic Dermatitis - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2014 46
Atopic Dermatitis - Pipeline by Eisai Co., Ltd., H2 2014 47
Atopic Dermatitis - Pipeline by LEO Pharma A/S, H2 2014 48
Atopic Dermatitis - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2014 49
Atopic Dermatitis - Pipeline by Pfizer Inc., H2 2014 50
Atopic Dermatitis - Pipeline by Celgene Corporation, H2 2014 51
Atopic Dermatitis - Pipeline by Bayer AG, H2 2014 52
Atopic Dermatitis - Pipeline by AlbireoPharma, H2 2014 53
Atopic Dermatitis - Pipeline by NicOx S.A., H2 2014 54
Atopic Dermatitis - Pipeline by Nuvo Research Inc., H2 2014 55
Atopic Dermatitis - Pipeline by Yungjin Pharm Ind. Co., Ltd., H2 2014 56
Atopic Dermatitis - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2014 57
Atopic Dermatitis - Pipeline by HanAll Biopharma Co., Ltd., H2 2014 58
Atopic Dermatitis - Pipeline by AnGes MG, Inc., H2 2014 59
Atopic Dermatitis - Pipeline by Provectus Biopharmaceuticals, Inc., H2 2014 60
Atopic Dermatitis - Pipeline by R-Tech Ueno, Ltd., H2 2014 61
Atopic Dermatitis - Pipeline by Paloma Pharmaceuticals, Inc., H2 2014 62
Atopic Dermatitis - Pipeline by Upsher-Smith Laboratories, Inc., H2 2014 63
Atopic Dermatitis - Pipeline by Foamix Ltd., H2 2014 64
Atopic Dermatitis - Pipeline by Anacor Pharmaceuticals, Inc., H2 2014 65
Atopic Dermatitis - Pipeline by AnaptysBio, Inc., H2 2014 66
Atopic Dermatitis - Pipeline by IMMD Inc., H2 2014 67
Atopic Dermatitis - Pipeline by Circassia Holdings Ltd., H2 2014 68
Atopic Dermatitis - Pipeline by Oxagen Limited, H2 2014 69
Atopic Dermatitis - Pipeline by Melior Discovery, Inc., H2 2014 70
Atopic Dermatitis - Pipeline by Grupo Ferrer Internacional, S.A., H2 2014 71
Atopic Dermatitis - Pipeline by Xencor, Inc., H2 2014 72
Atopic Dermatitis - Pipeline by Welichem Biotech Inc., H2 2014 73
Atopic Dermatitis - Pipeline by ChemoCentryx, Inc., H2 2014 74
Atopic Dermatitis - Pipeline by Vitae Pharmaceuticals, Inc., H2 2014 75
Atopic Dermatitis - Pipeline by arGEN-X BV, H2 2014 76
Atopic Dermatitis - Pipeline by SWITCH Biotech LLC, H2 2014 77
Atopic Dermatitis - Pipeline by Promius Pharma, LLC, H2 2014 78
Atopic Dermatitis - Pipeline by Celsus Therapeutics Plc, H2 2014 79
Atopic Dermatitis - Pipeline by Pharis Biotec GmbH, H2 2014 80
Atopic Dermatitis - Pipeline by Vicore Pharma AB, H2 2014 81
Atopic Dermatitis - Pipeline by Otsuka Holdings Co., Ltd., H2 2014 82
Atopic Dermatitis - Pipeline by LegoChem Biosciences, Inc, H2 2014 83
Atopic Dermatitis - Pipeline by Fountain Biopharma Inc., H2 2014 84
Atopic Dermatitis - Pipeline by Pergamum AB, H2 2014 85
Atopic Dermatitis - Pipeline by VivaCell Biotechnology Espana S.L., H2 2014 86
Atopic Dermatitis - Pipeline by Brickell Biotech, Inc., H2 2014 87
Atopic Dermatitis - Pipeline by NeoPharm Co., Ltd., H2 2014 88
Atopic Dermatitis - Pipeline by Herantis Pharma plc., H2 2014 89
Atopic Dermatitis - Pipeline by Creabilis SA, H2 2014 90
Atopic Dermatitis - Pipeline by sterna biologicals Gmbh & Co KG, H2 2014 91
Atopic Dermatitis - Pipeline by Dermira Inc., H2 2014 92
Atopic Dermatitis - Pipeline by Istituto Italiano di Tecnologia, H2 2014 93
Atopic Dermatitis - Pipeline by Thesan Pharmaceuticals, Inc., H2 2014 94
Atopic Dermatitis - Pipeline by ChironWells GmbH, H2 2014 95
Atopic Dermatitis - Pipeline by Pharmedartis GmbH, H2 2014 96
Assessment by Monotherapy Products, H2 2014 97
Number of Products by Stage and Target, H2 2014 100
Number of Products by Stage and Mechanism of Action, H2 2014 104
Number of Products by Stage and Molecule Type, H2 2014 110
Atopic Dermatitis Therapeutics - Recent Pipeline Updates, H2 2014 228
Atopic Dermatitis - Dormant Projects, H2 2014 264
Atopic Dermatitis - Dormant Projects (Contd..1), H2 2014 265
Atopic Dermatitis - Dormant Projects (Contd..2), H2 2014 266
Atopic Dermatitis - Dormant Projects (Contd..3), H2 2014 267
Atopic Dermatitis - Dormant Projects (Contd..4), H2 2014 268
Atopic Dermatitis - Dormant Projects (Contd..5), H2 2014 269
Atopic Dermatitis - Dormant Projects (Contd..6), H2 2014 270
Atopic Dermatitis - Discontinued Products, H2 2014 271